Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Anatomic complexity and tumor size were also higher among TSC-related AMLs.
|
31619031 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that varying stem cell dynamics and mutagenesis define TSC progression that may clinically translate into increasing tumor aggression with serious implications for prognosis.
|
16732329 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Allelic loss or loss of heterozygosity (LOH) in TSC lesions has previously been reported on chromosomes 16p13 and 9q34, the locations of the TSC2 and TSC1 genes, respectively, suggesting that the TSC genes act as tumor-suppressor genes.
|
8755927 |
1996 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recent investigation has found a lack of TSC gene mutation in these tumors compared with their nonrearranged counterparts, which underscores the importance of recognizing the translocated variant because of hypothetical ineffectiveness of targeted mTOR inhibitor therapy.
|
25517951 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our analyses revealed that the primary tumor and NCC-SS1-C1 cell line harbored the SS18-SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles.
|
29450702 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Here we review the current knowledge on how mutations within the TSC genes could trigger deregulation of stability and localization of the tumor suppressor p27.
|
16713332 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that combination of 3-BRPA and CB-839 may not offer a better therapeutic strategy than rapamycin for TSC-associated tumors.
|
30622053 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The lack of demonstrable inactivation of both alleles of either TSC gene in any of the tumours investigated suggests that they do not play a frequent role in the aetiology of sporadic glial or glioneuronal tumours.
|
11129334 |
2000 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings have clinical relevance in stratified medicine to treat tumors that have compromised signaling through TSC and are inflexible in their capacity to restore ER homeostasis.
|
29980790 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We suggest that the TSC gene on 16p13.3 functions like a tumour suppressor gene, in accordance with Knudsen's hypothesis.
|
8162074 |
1994 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, we analyze the impact of VHL alterations and HIF-α production on the expression of TSC proteins and Hsp90 in these tumors.
|
27845047 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Proteomic profiling revealed that the original tumor and the derived NCC-MFS1-C1 cells had similar, but distinct protein expression patterns.
|
30737712 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings provide novel functional links between the TSC genes and other tumor suppressors responsible for Cowden's disease (PTEN), Peutz-Jeghers syndrome (LKB1), and familial polyposis (APC).
|
15565817 |
2004 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TSC genes are considered to be tumor suppressor genes, and mutations in them may lead to abnormal differentiation and proliferation of cells.
|
11564212 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent work has indicated that the TSC1-TSC2 complex plays a role in the pathobiology of a number of tumor predisposition syndromes, including tuberous sclerosis (TSC1/2), Peutz-Jeghers syndrome (LKB1), and Cowden's syndrome (PTEN), in which the TSC/Rheb/mTOR axis is inappropriately active secondary to loss of tumor suppressor function.
|
15611656 |
2005 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tuberous sclerosis 2 (TSC2) gene is thought to function as a growth suppressor in sporadic and TSC-associated hamartomas and tumors.
|
9210877 |
1997 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Investigation of the mechanism of downregulation of TSC genes identified LOH in 36.96% and 39.13% of the tumors at the TSC1 and TSC2 loci, respectively.No mutation was found in TSC genes.
|
18538015 |
2008 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
TSC is caused by mutations affecting either of the presumed tumor-suppressor genes, TSC1 and TSC2.
|
10205261 |
1999 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cell lines have been established from angiomyolipomas, a common manifestation of LAM, and from tumors from patients with TSC.
|
29406787 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Forced expression of RARβ reversed the effects of miR-29b overexpression in proliferation, migration, and invasion, indicating that it is a critical target. miR-29b expression correlated with low RARβ expression in renal clear cell carcinomas and bladder urothelial carcinomas, tumors associated with TSC gene mutations.
|
31420607 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutations in human tuberous sclerosis complex (TSC) genes <i>TSC1</i> and <i>TSC2</i> are the leading causes of developmental brain abnormalities and large tumors in other tissues.
|
30050412 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in tuberous sclerosis (TSC) genes cause the genetic disorder TSC, as well as other neoplasms, including lymphangioleiomyomatosis (LAM) and angiomyolipomas (AMLs).
|
25476905 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this report, we describe tumor stem cell (TSC) marker CD133, CD15 and nestin alterations in ETANTR before and after chemotherapy.
|
23865520 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data support the hypothesis that both the TSC genes act as tumour suppressors and that the manifestations of TSC in patients with germline TSC mutations rise from "second hit" somatic mutations inactivating the remaining normal copy of the TSC gene.
|
8950679 |
1996 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The transfectant cells were found to be also reactive to the antibody NCC-ST-439, which was initially raised against human gastric cancer cells and later was shown to recognize a tumor-associated carbohydrate antigen in breast, gastric, and colon cancers.
|
9642161 |
1998 |